Japan approves sotrovimab for mild to moderate COVID-19 patients
The Health Ministry panel committee approved the use of sotrovimab, a single-dose monoclonal antibody treatment developed by GlaxoSmithKline and Vir Biotechnology, for mild and moderately ill COVID-19 patients.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan for full access to every Belfast Herald story and the complete archive.
HealthJapan approves sotrovimab for mild to moderate COVID-19 patients
Sign in or subscribeBrowse free archive reportsThe Health Ministry panel committee approved the use of sotrovimab, a single-dose monoclonal antibody treatment developed by GlaxoSmithKline and Vir Biotechnology, for mild and moderately ill COVID-19 patients.